Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-24-196 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or ce...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 5, 2024 Category: Research Source Type: funding
Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in ARIA (U24 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-24-034 from the NIH Guide for Grants and Contracts. The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2024 Category: Research Source Type: funding
Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional)
Funding Opportunity RFA-NS-25-014 from the NIH Guide for Grants and Contracts. "Fluctuating cognition can occur in many types of dementia and is a core clinical feature of Dementia with Lewy Bodies. Cognitive fluctuations can last from seconds to days, are unpredictable (e.g., do not just occur in the evenings, as with sun-downing), and are associated with poor daily functioning for the patient. A number of small studies have suggested that cognitive fluctuations in subjects with dementia may be related to epileptiform discharges and impaired oscillatory activity on EEG, but it is not clear that these are the only facto...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 18, 2024 Category: Research Source Type: funding
Notice of Change to Receipt Dates for RFA-NS-24-013: Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)
Notice NOT-NS-24-044 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 25, 2024 Category: Research Source Type: funding
Supporting Research in Health Disparities, Policy, and Ethics in Alzheimer's Disease and Dementia Research (HPE-ADRD)
Funding to increase understanding and develop strategies to address diversity, equity, and inclusion in Alzheimer's disease and related dementia research. Populations of focus include individuals living in geographies identified as underserved (rural and urban), among others. Geographic coverage: Nationwide -- Alzheimer's Association (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - November 20, 2023 Category: American Health Source Type: funding
Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)
Funding Opportunity RFA-NS-24-013 from the NIH Guide for Grants and Contracts. This RFA will solicit applications for a pivotal phase 3 clinical trial to determine the efficacy of FDA approved monoclonal antibody therapy compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions. Mixed dementia refers to dementia cases positive for 1) Alzheimer biomarkers, such as amyloid positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) evidence of vascular contributions based on imaging (white matter disease and/or subcl...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 19, 2023 Category: Research Source Type: funding
Request for Information (RFI) on the need for research studies to evaluate potential effects of types of blood pressure reducing agents on the development of mild cognitive impairment and dementia
Notice NOT-AG-23-039 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 2, 2023 Category: Research Source Type: funding
Notice of Pre-Application Webinar for RFA-AG-24-033, State Dementia Care Research Center (U54 Clinical Trial Not Allowed)
Notice NOT-AG-23-046 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 14, 2023 Category: Research Source Type: funding
Limited Competition: The Harmonized Cognitive Assessment Protocol (HCAP) Network (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-035 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications to continue critical ongoing network and infrastructure support for advancing development in a specific high-priority area of behavioral and social research on Alzheimers disease (AD) and AD-related dementias (ADRD): The Harmonized Cognitive Assessment Protocol (HCAP) International AD/ADRD Research Network. Network/infrastructure-building activities include but are not limited to meetings to develop novel research areas and interact on the development of infrastructure; small-scal...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 6, 2023 Category: Research Source Type: funding
State Dementia Care Research Center (U54 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-033 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites applications for a State Dementia Care Research Center (henceforth Center) which aims to ultimately improve care for persons living with dementia (PLWD) and their caregivers/care partners by building a research evidence base that can be used to improve dementia care coordination, integration, and care transitions in community settings, as well as inform policymaking. With recognition of the differences in provision, coverage, and access to Alzheimer's disease (AD) and Alzheimer's disease relat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 6, 2023 Category: Research Source Type: funding
Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care (R01 Clinical Trial Optional)
Funding Opportunity RFA-AG-24-031 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for R01 research projects that aim to advance economic research on Alzheimers disease (AD) and AD-related dementias (ADRD) by examining the development and diffusion of treatment/care innovations, payment and treatment models for care and care access for people living with dementia (PLWD) and their caregivers, and?economic factors influencing disease progression addressing AD/ADRD research implementation milestones?1.P,?13.P,?13.M, and?13.N. These projects will be linked to the Co...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 28, 2023 Category: Research Source Type: funding
Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care Coordinating Center (U54 Clinical Trial Optional)
Funding Opportunity RFA-AG-24-030 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for a U54 Specialized Center to advance economic research on Alzheimers disease (AD) and AD-related dementias (ADRD) by supporting a consortium of research projects examining the development and diffusion of treatment/care innovations, payment and treatment models for care, care quality and access for people living with dementia (PLWD) and their caregivers, as well as economic factors influencing disease progression to address NIA AD/ADRD research implementation milestones1.P,13.P...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 28, 2023 Category: Research Source Type: funding
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-24-009 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 26, 2023 Category: Research Source Type: funding
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-207 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 14, 2023 Category: Research Source Type: funding
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-208 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the develo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 14, 2023 Category: Research Source Type: funding
